ReviewCancers2020
Ductal Carcinoma In Situ of the Breast: An Update with Emphasis on Radiological and Morphological Features as Predictive Prognostic Factors.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- The impact of mammographic breast density on locoregional recurrence in breast cancer: a systematic review and meta-analysis.Breast cancer research and treatment · 2025Pooled it
- Sentinel lymph node biopsy in patients with ductal carcinoma in situ: systematic review and meta-analysis.BJS open · 2022Pooled it
- Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.The oncologist · 2024Trial
- Beyond Histology: Evaluating Ultrafast DCE MRI Texture Analysis for Breast DCIS Grading.Radiology. Imaging cancer · 2026Article
- Automated Cluster-based Quantitative Analysis of Ultrafast DCE MRI for Differential Breast DCIS Grading.Radiology. Imaging cancer · 2026Article
- Prediction of histological grading in ductal carcinomaFrontiers in oncology · 2026Article
- Prediction of upstaging in DCIS: the dominant role of pathological over imaging risk factors.Breast cancer research and treatment · 2025Article
- Article
- Article
- The clinicopathological features of breast cancer in Peutz-Jeghers syndrome: results from an international survey.Familial cancer · 2025Article
- Comparative Analyses of Van Nuys Prognostic Index and NCCN Guidelines in Ductal CarcinomaLife (Basel, Switzerland) · 2025Article
- Magnetic resonance imaging features and diagnostic value analysis of non-mass enhancement lesions of the breast.Quantitative imaging in medicine and surgery · 2025Article
- Assessing the malignancy of suspicious breast microcalcifications: the role of contrast enhanced mammography.La Radiologia medica · 2024Article
- Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance.Signal transduction and targeted therapy · 2024Review
- Unravelling the clinicopathological and functional significance of replication protein A (RPA) heterotrimeric complex in breast cancers.NPJ breast cancer · 2023Article
- Transcriptome analysis reveals differences in cell cycle, growth and migration related genes that distinguish fibroblasts derived from pre-invasive and invasive breast cancer.Frontiers in oncology · 2023Article
- Imaging of lumpectomy surface with large field-of-view confocal laser scanning microscope for intraoperative margin assessment - POLARHIS study.Breast (Edinburgh, Scotland) · 2022Article
- Is loss of p53 a driver of ductal carcinoma in situ progression?British journal of cancer · 2022Review
- Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2.Biomedicines · 2022Review
- Human study on cancer diagnostic probe (CDP) for real-time excising of breast positive cavity side margins based on tracing hypoxia glycolysis; checking diagnostic accuracy in non-neoadjuvant cases.Cancer medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ductal carcinoma in situ (DCIS) shows overlapping epidemiology with invasive ductal carcinoma of the breast, sharing similar risk factorssuch as age, mammographic density, family history, and hormonal therapy as well as genetic factors such as BRCA1/BRCA2, histotypes, and molecular subtypes such as luminal A and B, HER2 enriched, and basal-type, thus suggesting its potential precursor role. A small percentage of patients with a history of DCIS die without a documented intermediate diagnosis of invasive breast carcinoma (IBC). The increased risk of death is usually associated with ipsilateral recurrence such as IBC. The slightly variable incidence of DCIS in different countries is mainly due to a different diffusion of mammographic screening and variability of the risk factors. The majority of DCIS lesions are not palpable lesions, which can be only radiologically detected because of the association with microcalcifications. Mammography is a highly sensitive diagnostic procedure for detecting DCIS with microcalcifications, while magnetic resonance imaging (MRI) is considered more sensitive to detect DCIS without calcifications and/or multifocal lesions. The aim of the present overview was to focus on the clinical, radiological, and pathological features of DCIS of the breast, with an emphasis on the practical diagnostic approach, predictive prognostic factors, and therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.